[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 431
1. Sakhi AK, Russnes KM, Thoresen M, Bastani NE, Karlsen A, Smeland S, Blomhoff R: Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study. BMC Cancer; 2009;9:458
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study.
  • BACKGROUND: The purpose of this study was to compare plasma levels of antioxidants and oxidative stress biomarkers in head and neck squamous cell carcinoma (HNSCC) patients with healthy controls.
  • [MeSH-major] Biomarkers / blood. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / radiotherapy. Carotenoids / blood. Head and Neck Neoplasms / blood. Head and Neck Neoplasms / radiotherapy. Oxidative Stress

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2007 Aug;137(8):1951-4 [17634269.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1679-83 [18059031.001]
  • [Cites] Rapid Commun Mass Spectrom. 2009 Sep;23(18):2885-90 [19670343.001]
  • [Cites] Nutr Cancer. 2010;62(3):322-8 [20358469.001]
  • [Cites] Oral Oncol. 2000 Sep;36(5):466-70 [10964055.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1457-63 [11245451.001]
  • [Cites] N Engl J Med. 2001 Apr 12;344(15):1125-31 [11297703.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 [11368918.001]
  • [Cites] Free Radic Res. 2002 Aug;36(8):875-82 [12420746.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1895-901 [14534715.001]
  • [Cites] Biomed Pharmacother. 2004 Mar;58(2):100-10 [14992791.001]
  • [Cites] J Med Genet. 2004 May;41(5):360-5 [15121774.001]
  • [Cites] Arch Biochem Biophys. 2004 Oct 1;430(1):97-103 [15325916.001]
  • [Cites] J Nutr. 2004 Nov;134(11):3207S-3209S [15514309.001]
  • [Cites] Nutr Cancer. 1993;20(1):61-70 [8415131.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Jul;31B(4):253-7 [7492922.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Mar;32B(2):120-2 [8736174.001]
  • [Cites] Anal Biochem. 1996 Jul 15;239(1):70-6 [8660627.001]
  • [Cites] Biotherapy. 1998;11(2-3):147-54 [9677046.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):726-33 [15599850.001]
  • [Cites] Curr Opin Lipidol. 2005 Feb;16(1):47-54 [15650563.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5805-13 [16027437.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):132-8 [16046288.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2848-54 [16364999.001]
  • [Cites] J Chromatogr A. 2006 Feb 3;1104(1-2):179-89 [16376913.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Indian J Med Res. 2005 Dec;122(6):529-34 [16518005.001]
  • [Cites] Cancer Lett. 2006 Jul 18;238(2):240-7 [16157445.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] J Chromatogr A. 2007 Feb 23;1142(2):178-84 [17208244.001]
  • [Cites] Nutr Cancer. 2006;56(2):232-40 [17474870.001]
  • [Cites] Nutr Cancer. 2007;59(1):29-35 [17927499.001]
  • (PMID = 20025747.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 36-88-4 / Carotenoids
  • [Other-IDs] NLM/ PMC2813240
  •  go-up   go-down


2. Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM: The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med; 2005;3:27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects.
  • BACKGROUND: The purpose of the present investigation was to determine if the salivary counts of 40 common oral bacteria in subjects with an oral squamous cell carcinoma (OSCC) lesion would differ from those found in cancer-free (OSCC-free) controls.
  • When tested as diagnostic markers the 3 species were found to predict 80% of cancer cases (sensitivity) while excluding 83% of controls (specificity) in the non-matched group.
  • [MeSH-major] Bacteria / isolation & purification. Capnocytophaga / isolation & purification. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / microbiology. Mouth Neoplasms / diagnosis. Mouth Neoplasms / microbiology. Prevotella melaninogenica / isolation & purification. Saliva / microbiology. Streptococcus mitis / isolation & purification


3. Murphy N, Ring M, Heffron CC, King B, Killalea AG, Hughes C, Martin CM, McGuinness E, Sheils O, O'Leary JJ: p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol; 2005 May;58(5):525-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.
  • AIM: To analyse and compare expression patterns of three potential biomarkers-p16(INK4A), CDC6, and MCM5-and evaluate their use as predictive biomarkers in squamous and glandular cervical preinvasive neoplasia.
  • METHODS: Immunocytochemical analysis of p16(INK4A), MCM5, and CDC6 expression was performed on 20 normal, 38 cervical intraepithelial neoplasia 1 (CIN1), 33 CIN2, 46 CIN3, 10 squamous cell carcinoma, 19 cervical glandular intraepithelial neoplasia (cGIN), and 10 adenocarcinoma samples.
  • RESULTS: All three markers showed a linear correlation between expression and grade of dysplasia. p16(INK4A) and MCM5 protein expression was upregulated in all grades of squamous and glandular dysplasia.
  • CDC6 protein was preferentially expressed in high grade lesions and in invasive squamous cell carcinoma.
  • CONCLUSION: p16(INK4A) expression was closely associated with high risk HPV infection-all grades of squamous and glandular cervical lesions were immunohistochemically positive.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / complications. Adenocarcinoma / immunology. Antibodies, Monoclonal / immunology. Blotting, Western / methods. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / immunology. Female. Humans. Immunohistochemistry / methods. Neoplasm Proteins / analysis. Neoplasm Proteins / immunology. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Risk Factors

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12754-9 [10535995.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):537-41 [10675486.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):1929-38 [10806104.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2330-43 [10995389.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):690-6 [11063933.001]
  • [Cites] J Pathol. 2001 Mar;193(3):295-302 [11241407.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):544-50 [11297246.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):1063-6 [11496317.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1347-52 [11805305.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2758-67 [9566895.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):580-5 [9736404.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] EMBO J. 1999 Jan 15;18(2):396-410 [9889196.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2299-309 [10327050.001]
  • [Cites] Cancer Lett. 1999 Mar 1;136(2):231-5 [10355753.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):458-67 [10408854.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25927-32 [10464337.001]
  • [Cites] Gut. 2002 Mar;50(3):290-1 [11839701.001]
  • [Cites] Gut. 2002 Mar;50(3):373-7 [11839717.001]
  • [Cites] BJOG. 2001 Dec;108(12):1204-13 [11843381.001]
  • [Cites] J Cell Sci. 2002 Mar 1;115(Pt 5):869-72 [11870205.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1917-9 [12057556.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25431-8 [12006585.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1164-8 [12296751.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Virus Res. 2002 Nov;89(2):271-4 [12445666.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:s81-91 [12456298.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):704-12 [12554670.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):257-62 [12610511.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • [Cites] Eur J Biochem. 2003 Mar;270(6):1089-101 [12631269.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):997-1008 [12718885.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):118-20 [12861148.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):472-9 [12911724.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] J Pathol. 2003 Sep;201(1):109-18 [12950023.001]
  • [Cites] Int J Gynecol Pathol. 2003 Oct;22(4):378-85 [14501820.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):38059-67 [12837750.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5816-20 [7954407.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6078-82 [7954450.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):442-5 [8621224.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(3):1040-6 [11846807.001]
  • (PMID = 15858126.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / CDC6 protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Schizosaccharomyces pombe Proteins; 0 / mcm5 protein, S pombe
  • [Other-IDs] NLM/ PMC1770660
  •  go-up   go-down


Advertisement
4. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


5. Czito BG, Willett CG: Current management of anal canal cancer. Curr Oncol Rep; 2009 May;11(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of anal canal cancer.
  • Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence.
  • At present, RT with 5-FU and mitomycin is the standard of care for anal cancer patients.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Dis Colon Rectum. 2008 Feb;51(2):147-53 [18180997.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1020-2 [16505418.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5281-6 [18024876.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):390-5 [6401588.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1057-63 [16505424.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • (PMID = 19336010.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Number-of-references] 24
  •  go-up   go-down


6. Vieira FL, Vieira BJ, Guimaraes MA, Aarestrup FM: Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading. BMC Oral Health; 2008;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading.
  • BACKGROUND: Squamous cells carcinoma is the most important malignant tumor with primary site in the oral cavity and, given the great exposure of mucosa and lips to the etiologic factors of this neoplasm, its incidence is high.
  • METHODS: In this study, oral mucosa samples of squamous cells carcinoma were analyzed, separated according to their histological classification as well as the phenotypical profile of the cells comprising the peritumoral inflammatory infiltrate was investigated by immunohistochemical method, in addiction, the cell proliferation index via protein Ki67 expression was determinated.
  • The immunohistochemical assessment of Ki-67 positive cells revealed a greater expression of this protein in samples of undifferentiated squamous cells carcinoma.
  • CONCLUSION: The results suggest that the cellular immune response is the main defense mechanism in squamous cells carcinoma of oral mucosa, expressed by the large number of T lymphocytes and macrophages, and that the greatest intensity of local response may be associated with the best prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAAPA. 2007 Oct;20(10):42-7 [18019328.001]
  • [Cites] Oral Oncol. 2001 Feb;37(2):164-71 [11167144.001]
  • [Cites] Acta Otorrinolaringol Esp. 2007 Oct;58(8):341-6 [17949660.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Aug;36(8):671-9 [17643963.001]
  • [Cites] Minerva Stomatol. 2007 Jun;56(6):341-7 [17625491.001]
  • [Cites] Pancreatology. 2006;6(5):450-3 [16847382.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):329-34 [16820911.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Braz J Otorhinolaryngol. 2005 Mar-Apr;71(2):181-7 [16446915.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):57-61 [16390239.001]
  • [Cites] Br J Oral Maxillofac Surg. 2005 Dec;43(6):511-2 [15908082.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):671-6 [15625605.001]
  • [Cites] Harefuah. 2005 Apr;144(4):243-5, 304, 303 [15889605.001]
  • [Cites] Br J Oral Maxillofac Surg. 2005 Jun;43(3):253-5 [15888363.001]
  • [Cites] J Periodontol. 2005 Mar;76(3):406-10 [15857075.001]
  • [Cites] Laryngoscope. 2005 Apr;115(4):690-8 [15805883.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):64-70 [15599350.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Arch Pathol Lab Med. 1998 May;122(5):447-54 [9593347.001]
  • [Cites] Aust Dent J. 1996 Apr;41(2):91-6 [8670041.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):25-39 [2488698.001]
  • [Cites] Acta Pathol Jpn. 1993 Mar;43(3):99-106 [8484337.001]
  • [Cites] Br J Oral Surg. 1983 Jun;21(2):136-46 [6575816.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1319-29 [15319236.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2004 Apr;22(2):109-11 [15190789.001]
  • [Cites] Shanghai Kou Qiang Yi Xue. 2002 Dec;11(4):350-2 [14983378.001]
  • [Cites] Oral Oncol. 2003 Jul;39(5):459-69 [12747970.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38159-67 [12138162.001]
  • [Cites] Exp Cell Res. 2001 Nov 1;270(2):259-67 [11640889.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3661-6 [17972532.001]
  • (PMID = 18764952.001).
  • [ISSN] 1472-6831
  • [Journal-full-title] BMC oral health
  • [ISO-abbreviation] BMC Oral Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556313
  •  go-up   go-down


7. Nilsson PJ, Lenander C, Rubio C, Auer G, Ljungqvist O, Glimelius B: Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep; 2006 Sep;16(3):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Cyclin A in epidermoid anal cancer.
  • Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers.
  • From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry.
  • Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
  • [MeSH-major] Anus Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865241.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Pignataro L, Pagani D, Brando B, Sambataro G, Scarpati B, Corsi MM: Down-regulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma. Anal Quant Cytol Histol; 2007 Feb;29(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of zeta chain and zeta-associated protein 70 (Zap 70) expression in circulating T lymphocytes in laryngeal squamous cell carcinoma.
  • OBJECTIVE: To evaluate zeta chain and Zap 70 expression in T lymphocytes of patients with laryngeal cancer in relation to surgical treatment.
  • STUDY DESIGN: This study investigated, by dual-color flow cytometry, zeta chain and Zap 70 expression in the circulating T lymphocytes of 13 patients with laryngeal cancer patients before and after surgical treatment.
  • CONCLUSION: The results of this investigation seem to indicate that both the zeta chain and the Zap 70 expression in circulating T lymphocytes are down-regulated in patients with laryngeal cancer and that these changes do not immediately return to normal after surgery.
  • Flow cytometry analysis may represent an easy-to-use procedure for monitoring the immune status of patients with laryngeal cancer.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375875.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Antigen, T-Cell; 0 / antigen T cell receptor, zeta chain; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


9. Schlecht HP, Fugelso DK, Murphy RK, Wagner KT, Doweiko JP, Proper J, Dezube BJ, Panther LA: Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis; 2010 Jul 1;51(1):107-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men.
  • Human papillomavirus causes anal condylomata, high-grade anal intraepithelial neoplasia, and anal squamous cell cancer.
  • We found high-grade intraepithelial neoplasia or squamous cell cancer in 75 (47%) of 159 HIV-seropositive men who have sex with men (MSM) and in 42 (26%) of 160 HIV-seronegative MSM with anal condylomata meriting surgery (P<.001, determined by use of the chi(2) test).
  • Anal condylomata in MSM often harbor high-grade intraepithelial neoplasia and squamous cell cancer.
  • [MeSH-major] Anus Diseases / complications. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Condylomata Acuminata / complications. Homosexuality, Male. Papillomavirus Infections / complications


10. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M: Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc; 2009 May;23(5):1054-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy.
  • BACKGROUND: Radiochemotherapy has largely replaced surgery in the treatment for squamous cell cancer of the anal canal.
  • Transanal ultrasonography is well documented as an important investigation method in the management of anal carcinoma.
  • METHODS: The study enrolled 16 consecutive patients with biopsy-proven squamous carcinoma of the anal canal between 2003 and 2006.
  • CONCLUSIONS: Endoanal ultrasound is a safe and effective method for evaluating and following anal cancer before and after treatment.
  • Experience and evaluation during the period of the ultrasonographic abnormalities could give a clear idea concerning the evolution of the anal tumors treated with radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Endosonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):77-92 [12098609.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):359-64 [10433044.001]
  • [Cites] Surg Clin North Am. 2004 Aug;84(4):1127-49, vii [15261756.001]
  • [Cites] Surg Endosc. 1994 Oct;8(10 ):1186-9 [7809802.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):839-42 [15085443.001]
  • [Cites] Eur J Radiol. 2003 Aug;47(2):142-8 [12880995.001]
  • (PMID = 18813993.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Malhotra R, Patel V, Vaqué JP, Gutkind JS, Rusling JF: Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. Anal Chem; 2010 Apr 15;82(8):3118-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification.
  • Squamous cell carcinomas of head and neck (HNSCC) are associated with immune, inflammatory, and angiogenic responses involving interleukin-6 (IL-6).

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2000 Jan;46(1):105-11 [10620578.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2422-8 [17438101.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1911-28 [17849470.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Dec;19(10):769-76 [17950585.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):268-78 [18337732.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] Analyst. 2008 Aug;133(8):975-83 [18645635.001]
  • [Cites] J Nanosci Nanotechnol. 2009 Jan;9(1):249-55 [19441303.001]
  • [Cites] Ann Clin Biochem. 2001 Nov;38(Pt 6):633-51 [11732646.001]
  • [Cites] Anal Chem. 2009 Nov 1;81(21):9129-34 [19775154.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2948-56 [12782602.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:133-9 [14656269.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):179-96 [15113093.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:9-16 [15251933.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):249-58 [15352037.001]
  • [Cites] J Clin Chem Clin Biochem. 1979 Jan;17(1):1-7 [33227.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 31;230(1-2):95-106 [15664456.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Annu Rev Immunol. 2005;23:1-21 [15771564.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2761-5 [16080523.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):347-63 [16309541.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):310-20 [16582876.001]
  • [Cites] Anal Chem. 2006 Jul 1;78(13):4260-9 [16856252.001]
  • [Cites] Mol Biosyst. 2005 May;1(1):70-8 [16880966.001]
  • [Cites] J Am Chem Soc. 2006 Aug 30;128(34):11199-205 [16925438.001]
  • [Cites] Analyst. 2007 Aug;132(8):724-37 [17646870.001]
  • (PMID = 20192182.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES013557; United States / NIEHS NIH HHS / ES / ES013557-04; United States / Intramural NIH HHS / / ; United States / NIEHS NIH HHS / ES / ES013557; United States / NIEHS NIH HHS / ES / R01 ES013557-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Nanotubes, Carbon
  • [Other-IDs] NLM/ NIHMS183623; NLM/ PMC2854872
  •  go-up   go-down


12. Irabor DO, Dongo AE: Anal carcinoma in a tropical low socio-economic population in the new millennium: What has changed? Trop Doct; 2009 Jan;39(1):7-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in a tropical low socio-economic population in the new millennium: What has changed?
  • The paper is a retrospective look at the clinicopathological presentation of carcinoma of the anal canal in a tertiary health institution in Nigeria.
  • Sixty-five patients were diagnosed with anal carcinoma over a five-year period (2002-2006) from a total of 394 patients who had malignancies of the colon, rectum and anus.
  • The male: female ratio was 1.2: 1 showing a slight male predominance; the average age was 48 years; tenesmus, bleeding per rectum and anal pain were the most common presenting features.
  • The most predominant histopathological subtype was adenocarcinoma - a departure from the hitherto squamous cell cancer dominance.
  • [MeSH-major] Adenocarcinoma. Anus Neoplasms. Carcinoma
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Nigeria / epidemiology. Socioeconomic Factors. Tropical Climate. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211411.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


14. Kovar JL, Volcheck WM, Chen J, Simpson MA: Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice. Anal Biochem; 2007 Feb 1;361(1):47-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Binding of IRDye 800CW EGF to intact A431 human epidermoid carcinoma cells was quantified in a microplate assay.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epidermal Growth Factor

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14 [12154371.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):849-57 [12213713.001]
  • [Cites] Amino Acids. 2002;23(1-3):301-8 [12373551.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S9-14 [12867057.001]
  • [Cites] Curr Opin Chem Biol. 2003 Oct;7(5):626-34 [14580568.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]
  • [Cites] Mol Imaging. 2003 Oct;2(4):303-12 [14717329.001]
  • [Cites] Nat Biotechnol. 2004 Feb;22(2):198-203 [14704683.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):481-8 [15078992.001]
  • [Cites] Mol Imaging. 2004 Jan;3(1):9-23 [15142408.001]
  • [Cites] Science. 1977 Dec 23;198(4323):1264-7 [929199.001]
  • [Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1415-26 [17003496.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):327-31 [11283589.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):136-42 [15707944.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8009-14 [15520209.001]
  • [Cites] Biochemistry. 1993 Nov 16;32(45):12039-45 [8218281.001]
  • [Cites] Curr Opin Oncol. 1993 May;5(3):474-80 [8494908.001]
  • [Cites] Annu Rev Biophys Biophys Chem. 1991;20:1-28 [1867711.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1433-41 [16287239.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41205 [16178629.001]
  • [Cites] Drugs Today (Barc). 2005 Feb;41(2):107-27 [15821783.001]
  • (PMID = 17188228.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106584
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Indicators and Reagents; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS16673; NLM/ PMC1866276
  •  go-up   go-down


15. Herat A, Shirato K, Damian DL, Finlayson R, Whitfeld M: Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual. Australas J Dermatol; 2006 May;47(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual.
  • Perianal Bowen's disease represents high-grade anal intraepithelial neoplasia, which is considered a precursor lesion of invasive anal squamous cell carcinoma.
  • This patient's anal intraepithelial neoplasia was unresponsive to multiple treatment modalities including cryotherapy, serial curettage and cautery, topical 5-fluorouracil and 5-aminolaevulinic acid photodynamic therapy.
  • He progressed to develop a poorly differentiated squamous cell carcinoma of the anus three and a half years after the Bowen's disease was diagnosed.
  • The squamous cell carcinoma was treated with combined chemoradiation.
  • A recurrence of high-grade anal intraepithelial neoplasia was noted 6 months after completion of chemoradiation.
  • [MeSH-major] Bowen's Disease / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Diagnosis, Differential. Homosexuality, Male. Humans. Male. Middle Aged. Neoplasm Invasiveness


16. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene; 2005 Feb 24;24(9):1491-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.
  • By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.
  • The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial-mesenchymal signaling in these early neoplastic lesions.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • eagle-i research resources. PMID 15674344 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]
  • [Cites] Cancer Surv. 1998;32:69-113 [10489624.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]
  • [Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]
  • [Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • [Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]
  • [Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]
  • [Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]
  • [Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]
  • [Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • (PMID = 15674344.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530
  •  go-up   go-down


18. Schneider FT, Schänzer A, Czupalla CJ, Thom S, Engels K, Schmidt MH, Plate KH, Liebner S: Sonic hedgehog acts as a negative regulator of {beta}-catenin signaling in the adult tongue epithelium. Am J Pathol; 2010 Jul;177(1):404-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show Wnt/beta-catenin pathway activation in reporter mice and by nuclear beta-catenin staining in the epithelium and taste papilla of adult mouse and human tongues. beta-Catenin activation in APC(min/+) mice, which carry a mutation in adenomatous poliposis coli (APC), up-regulates Sonic hedgehog (Shh) and Jagged-2 (JAG2) in the tongue epithelium without formation of squamous cell carcinoma (SCC).
  • At the invasive front of human tongue cancer, nuclear beta-catenin and Shh were increased, suggesting their participation in tumor progression.
  • Interestingly, Shh but not JAG2 was able to reduce beta-catenin signaling in SCC cells, arguing for a partial loss of negative feedback on beta-catenin transcription in tongue cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line. Female. Genes, Reporter. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Mice. Mice, Inbred C57BL. Middle Aged. Tongue Neoplasms / metabolism. Tongue Neoplasms / pathology. Transcriptional Activation

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7794-800 [15520185.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Development. 2005 Apr;132(8):1819-30 [15772135.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Trends Cell Biol. 2005 May;15(5):234-7 [15866026.001]
  • [Cites] Cell Signal. 2006 May;18(5):679-87 [16084063.001]
  • [Cites] Cell Mol Life Sci. 2006 Jun;63(11):1249-65 [16596340.001]
  • [Cites] Biol Cell. 2006 Aug;98(8):479-90 [16608439.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):221-7 [16598417.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2654-9 [17015430.001]
  • [Cites] Development. 2006 Nov;133(22):4427-38 [17035290.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):106-12 [17128274.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):189-98 [17237784.001]
  • [Cites] Cell. 2007 Feb 9;128(3):445-58 [17289566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2253-8 [17284610.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):1023-36 [17675579.001]
  • [Cites] J Pathol. 2008 Jan;214(1):3-9 [18067118.001]
  • [Cites] Curr Biol. 2008 Mar 25;18(6):R238-41 [18364223.001]
  • [Cites] J Comp Neurol. 2008 Jul 10;509(2):211-24 [18465790.001]
  • [Cites] Nat Genet. 2008 Sep;40(9):1130-5 [19165927.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6315-20 [19325125.001]
  • [Cites] J Pathol. 2009 Jul;218(3):370-9 [19347947.001]
  • [Cites] J Invest Dermatol. 2009 Jul;129(7):1614-27 [19177135.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):629-38 [19427313.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7577-86 [19738061.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Development. 2000 May;127(10):2075-87 [10769232.001]
  • [Cites] Anal Biochem. 2000 Jun 15;282(1):158-61 [10860516.001]
  • [Cites] Mech Dev. 2001 Aug;106(1-2):143-5 [11472844.001]
  • [Cites] J Oral Pathol Med. 2002 Aug;31(7):385-94 [12165056.001]
  • [Cites] Dev Biol. 2003 Feb 1;254(1):1-18 [12606278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3299-304 [12626757.001]
  • [Cites] Am J Med Genet A. 2003 Nov 15;123A(1):5-28 [14556242.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Arch Oral Biol. 2004 Aug;49(8):653-64 [15196983.001]
  • [Cites] J Cell Biol. 2004 Aug 2;166(3):359-67 [15289495.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] J Comp Neurol. 1999 Apr 5;406(2):143-55 [10096602.001]
  • [Cites] Mech Dev. 1999 Mar;81(1-2):65-74 [10330485.001]
  • [Cites] Dev Biol. 2004 Dec 15;276(2):280-300 [15581865.001]
  • (PMID = 20508033.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / JAG2 protein, human; 0 / Jag2 protein, mouse; 0 / Membrane Proteins; 0 / SHH protein, human; 0 / Shh protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2893682
  •  go-up   go-down


19. Dwyer MK, Gebski VJ, Jayamohan J: The bottom line: outcomes after conservation treatment in anal cancer. Australas Radiol; 2006 Feb;50(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bottom line: outcomes after conservation treatment in anal cancer.
  • At the Department of Radiation Oncology, Westmead Hospital, between 1980 and 2000, 60 patients with squamous cell carcinoma of anal canal or margin (including 15 with Stage IIIA or IIIB) were treated radically; 55 received chemoradiation (89% were prescribed mitomycin C and 5-fluorouracil).
  • Most patients with anal cancer can expect to retain a functional sphincter after chemoradiation/radiation.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499727.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


21. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J, Kim KT: Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol; 2008 Sep;19(3):173-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.
  • OBJECTIVE: To compare plasma protein expression between patients with squamous cell carcinoma (SCC) of the cervix and normal controls.
  • METHODS: Plasma samples from patients with benign gynecological disease (normal cervix, n=6) and cervical cancer (SCC, n=6) were subjected to plasma proteomic analysis using two dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS).
  • Immunoturbidimetric assay of a larger group confirmed the results of 2-DE and Western blotting, and showed that ceruloplasmin and complement C3 were significantly elevated in the plasma of SCC patients in comparison with controls and patients with carcinoma in situ (CIS) of the uterine cervix.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 May;140(5):1039-43 [1374587.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2363-7 [3458201.001]
  • [Cites] J Trace Elem Med Biol. 2004;18(1):1-8 [15487757.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jul;67(7):1574-7 [12913303.001]
  • [Cites] Immunol Rev. 2001 Apr;180:35-48 [11414361.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):629-32 [11299817.001]
  • [Cites] Cancer Lett. 2000 Nov 28;160(2):229-36 [11053653.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Mol Immunol. 1999 Sep-Oct;36(13-14):929-39 [10698347.001]
  • [Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • [Cites] Electrophoresis. 2007 Jun;28(12):1989-96 [17503403.001]
  • [Cites] Clin Chim Acta. 2007 Feb;377(1-2):119-26 [17067565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):299-310 [16924372.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1216-24 [16803509.001]
  • [Cites] Proteomics. 2006 May;6(9):2865-73 [16586433.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):20-8 [16537992.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4581-8 [16240287.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1073-85 [16083256.001]
  • [Cites] Adv Clin Chem. 2005;39:159-84 [16013671.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):889-99 [15952736.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4613-9 [15741220.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):895-905 [15726105.001]
  • [Cites] Immunopharmacology. 1999 May;42(1-3):39-45 [10408364.001]
  • [Cites] Int Urol Nephrol. 1997;29(4):427-32 [9405999.001]
  • [Cites] Biotechnology (N Y). 1996 Jan;14(1):61-5 [9636313.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1329-35 [8958307.001]
  • [Cites] Gut. 1996 Feb;38(2):248-53 [8801206.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):129-42 [8686736.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18149-54 [7517938.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5481-4 [7509788.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5B):2201-3 [7840524.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1406-12 [8381706.001]
  • (PMID = 19471570.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676467
  • [Keywords] NOTNLM ; MALDI-MS / Plasma proteins / Squamous cell carcinoma / Two dimensional gel electrophoresis / Uterine cervical cancer
  •  go-up   go-down


22. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Our previous study using proteomic profiling showed that significant upregulation of stathmin occurs in oral squamous-cell carcinoma (OSCC)-derived cell lines.
  • These results suggest that expression of stathmin could contribute to cancer progression/prognosis, and that stathmin may have potential as a biomarker and a therapeutic target for OSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


23. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer; 2006 Feb 27;94(4):561-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing.
  • Methylation profiling of cancer tissues has identified this mechanism as an important component of carcinogenesis.
  • We have investigated quantitative methylation status in oral squamous cell carcinoma patients.
  • Fresh tumour tissue and normal control tissue from resection margin was obtained from 79 consecutive patients undergoing resection of oral squamous cell carcinoma.
  • Cytoglobin is a novel candidate tumour suppressor gene highly methylated in upper aero-digestive tract squamous cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cyclin A / genetics. DNA Methylation. Mouth Neoplasms / genetics. Peroxidases / genetics

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):892-5 [10706101.001]
  • [Cites] Nucleic Acids Res. 1994 Dec 11;22(24):5354-9 [7816625.001]
  • [Cites] FEBS Lett. 2001 Feb 9;490(1-2):75-8 [11172814.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):386-92 [11900224.001]
  • [Cites] Mol Biol Evol. 2002 Apr;19(4):416-21 [11919282.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19538-45 [11893755.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4231-6 [12082610.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4757-66 [12183435.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6395-402 [12214281.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5295-300 [12234999.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3164-71 [12374684.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):109-14 [12406555.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):163-9 [12509970.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3971-5 [12553020.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):41-6 [12672028.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Jun;32(3):233-45 [12767868.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] Adv Exp Med Biol. 2003;532:39-49 [12908548.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2656-9 [7780981.001]
  • [Cites] Ann R Coll Surg Engl. 1996 Jan;78(1 Suppl):14-8 [8659993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):459-70 [9949205.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3518-26 [10416619.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] IUBMB Life. 2004 Nov-Dec;56(11-12):703-7 [15804835.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):1002-6 [15467435.001]
  • [Cites] Mol Carcinog. 2005 Jul;43(3):141-54 [15937959.001]
  • [Cites] Oral Oncol. 2005 Nov;41(10):1034-43 [16129652.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):101-8 [16154320.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2306-9 [14556921.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8902-11 [14654786.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):145-53 [14693237.001]
  • [Cites] Curr Oncol Rep. 2004 Mar;6(2):152-61 [14751093.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1733-42 [15014026.001]
  • [Cites] Hum Genet. 2004 May;114(6):534-40 [15007728.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3825-30 [15173091.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):389-95 [15254736.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5455-63 [15328184.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5982-7 [15342377.001]
  • [Cites] Anal Biochem. 2004 Oct 1;333(1):119-27 [15351288.001]
  • [Cites] Scand J Dent Res. 1986 Aug;94(4):347-56 [3462898.001]
  • [Cites] Nucleic Acids Res. 1990 Feb 11;18(3):687 [1689825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Oral Oncol. 2000 Sep;36(5):404-13 [10964046.001]
  • (PMID = 16449996.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCNA1 protein, human; 0 / Cadherins; 0 / Cyclin A; 0 / Cyclin A1; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Retinoic Acid; 0 / cytoglobin; 0 / retinoic acid receptor beta; 9004-22-2 / Globins; EC 1.11.1.- / Peroxidases
  • [Other-IDs] NLM/ PMC2361183
  •  go-up   go-down


24. Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH: Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs; 2007 Aug;25(4):327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the elimination pathways of ixabepilone we initiated a mass balance study in cancer patients.
  • Eight patients with advanced cancer (3 males, 5 females; median age 54.5 y; performance status 0-2) received an intravenous dose of 70 mg, 80 nCi of [14C]ixabepilone over 3 h.
  • [MeSH-minor] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Chromatography, Liquid / methods. Colonic Neoplasms / metabolism. Feces / chemistry. Female. Humans. Lung Neoplasms / metabolism. Male. Middle Aged. Ovarian Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. Sigmoid Neoplasms / metabolism. Tandem Mass Spectrometry / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17118-25 [9202030.001]
  • [Cites] Annu Rev Med. 1997;48:353-74 [9046968.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Science. 2004 Aug 6;305(5685):866-9 [15297674.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84 [14988742.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):233-40 [12612650.001]
  • [Cites] Suppl Tumori. 2002 Jul-Aug;1(4):S17-8 [12415808.001]
  • [Cites] Curr Pharm Des. 2002;8(19):1707-12 [12171542.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2035-43 [12114401.001]
  • [Cites] Drug Metab Dispos. 2002 Jul;30(7):823-30 [12065441.001]
  • [Cites] Chembiochem. 2000 Jul 3;1(1):67-70 [11828400.001]
  • [Cites] Curr Drug Metab. 2000 Sep;1(2):205-13 [11465084.001]
  • [Cites] Clin Pharmacokinet. 2000 Dec;39(6):429-43 [11192475.001]
  • [Cites] J Pharm Biomed Anal. 2000 Dec 15;24(2):197-209 [11130199.001]
  • [Cites] Mutat Res. 2000 Dec 20;472(1-2):119-27 [11113704.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Jun;15(6):691-702 [16732719.001]
  • [Cites] Mutat Res. 1998 Jun 18;402(1-2):67-75 [9675247.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] Clin Pharmacokinet. 2006;45(1):33-58 [16430310.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):539-45 [9935154.001]
  • (PMID = 17347871.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ PMC1915607
  •  go-up   go-down


25. Devaraj B, Cosman BC: Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum; 2006 Jan;49(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expectant management of anal squamous dysplasia in patients with HIV.
  • PURPOSE: Anal squamous dysplasia is commonly found in patients with HIV infection.
  • This study reviews a series of patients with HIV and an abnormal anal examination who had squamous dysplasia and who have been followed with physical examination alone and with repeat biopsies as necessary for new or suspicious lesions.
  • METHODS: We reviewed the charts of 40 HIV-positive men who had squamous dysplasia of the anal canal and anal margin, focusing on history, physical findings, histologic diagnosis, and the occurrence of invasive squamous-cell carcinoma.
  • RESULTS: Forty HIV-positive men (mean age, 39 years) were followed for anal squamous dysplasia.
  • Three patients developed invasive carcinoma while under surveillance, and these were completely excised or cured with chemoradiation.
  • In a group of patients followed expectantly, most did not develop invasive cancer, and in those who did, early cancers could be identified and cured.
  • Physical examination surveillance for invasive carcinoma may be acceptable for following patients with HIV and biopsy-proven squamous dysplasia.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colectomy / methods. Decision Making. HIV / immunology. HIV Antibodies / immunology. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50 [16972138.001]
  • (PMID = 16283561.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Antibodies
  •  go-up   go-down


26. Nordenvall C, Nyrén O, Ye W: Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions. Gut; 2006 May;55(5):703-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anal squamous cell carcinoma risk associated with benign inflammatory anal lesions.
  • BACKGROUND: The association between benign anal lesions and anal cancer is still unclear.
  • METHODS: We conducted a register based retrospective cohort study including 45,186 patients hospitalised for inflammatory anal lesions (anal fissures, fistulas, and perianal abscesses) as well as 79,808 haemorrhoid patients, from 1965 to 2002.
  • Multiple record linkages identified all incident anal (squamous cell carcinoma only) and colorectal cancers through to 2002.
  • Among inflammatory lesion and haemorrhoid patients, a significantly increased risk of colorectal cancer was observed only in the first year after hospitalisation.
  • CONCLUSIONS: Inflammatory benign anal lesions are associated with a significantly increased long term risk of anal cancer.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications
  • [MeSH-minor] Adult. Anus Diseases / complications. Anus Diseases / immunology. Female. Fissure in Ano / complications. Follow-Up Studies. Hemorrhoids / complications. Humans. Inflammation. Male. Middle Aged. Rectal Fistula / complications. Retrospective Studies. Risk Assessment

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol Oncol. 1984;23(5):305-13 [6095600.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Prog Growth Factor Res. 1992;4(2):121-37 [1338573.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):190-1 [7695719.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Gut. 1997 Oct;41(4):522-5 [9391253.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1047-52 [10201481.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):473-83 [11506482.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G626-34 [11518674.001]
  • [Cites] J Physiol Paris. 2001 Jan-Dec;95(1-6):417-22 [11595469.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • (PMID = 16299038.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1856114
  •  go-up   go-down


27. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ, Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA, Verma A: Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem; 2008 Aug 15;283(33):22700-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.
  • High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors.
  • Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma.
  • We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1alpha (HIF-1alpha) by glycolytic metabolites.
  • In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype.
  • Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2006 Jun;9(6):425-34 [16766262.001]
  • [Cites] Biochem Soc Trans. 2006 Apr;34(Pt 2):217-22 [16545080.001]
  • [Cites] Anal Chem. 2006 Jul 1;78(13):4281-90 [16808434.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):44-50 [16859625.001]
  • [Cites] PLoS Med. 2006 Aug;3(8):e327 [16933966.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10855-60 [17108122.001]
  • [Cites] Lab Invest. 2007 Jan;87(1):84-92 [17170741.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):37-51 [17222789.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(3):912-25 [17101781.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):3293-301 [17135241.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4524-32 [17182618.001]
  • [Cites] Histol Histopathol. 2007 May;22(5):559-72 [17330811.001]
  • [Cites] Cell Mol Life Sci. 2007 Apr;64(7-8):830-49 [17310282.001]
  • [Cites] Blood. 2007 May 1;109(9):3812-9 [17255361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7540-5 [17456604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 29;104(22):9445-50 [17517659.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1115-24 [17567242.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1382-7 [17965722.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Cancer Biol Ther. 2007 Sep;6(9):1476-9 [17881895.001]
  • [Cites] Chem Res Toxicol. 2000 Apr;13(4):231-6 [10775321.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3290-3 [11309282.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6820-7 [11687961.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23111-5 [11943784.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 21;1645(2):183-92 [12573248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4879-84 [12668764.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1764-8 [12702559.001]
  • [Cites] Mutagenesis. 2003 May;18(3):287-92 [12714696.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2003 Jun;135(2):119-28 [12860050.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(16):2195-204 [15279558.001]
  • [Cites] Toxicology. 2004 Oct 15;203(1-3):83-98 [15363585.001]
  • [Cites] Diabetes Care. 1992 Jun;15(6):785-91 [1600837.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63 [9192621.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):999-1006 [15705901.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):41928-39 [16223732.001]
  • [Cites] Cell Metab. 2006 Mar;3(3):177-85 [16517405.001]
  • [Cites] Cell Metab. 2006 Mar;3(3):187-97 [16517406.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • (PMID = 18541534.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113506; United States / NIDDK NIH HHS / DK / DK47844; United States / NCI NIH HHS / CA / P50 CA96784; United States / NINDS NIH HHS / NS / NS73814; United States / NIDCR NIH HHS / DE / R01DE015939
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Pyruvate Dehydrogenase Complex
  • [Other-IDs] NLM/ PMC2504897
  •  go-up   go-down


28. Membrilla-Fernández E, Parés D, Alameda F, Pascual M, Courtier R, Gil MJ, Vallecillo G, Fusté P, Pera M, Grande L: [Anal intraepithelial neoplasia: application of a diagnostic protocol in risk patients using anal cytology]. Cir Esp; 2009 Jun;85(6):365-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal intraepithelial neoplasia: application of a diagnostic protocol in risk patients using anal cytology].
  • [Transliterated title] Neoplasia intraepitelial anal: resultados de la aplicación de un protocolo diagnóstico en pacientes de riesgo mediante el uso de citología anal.
  • INTRODUCTION: Anal intraepithelial neoplasia is a precursor condition of squamous anal carcinoma.
  • The aim of this study was to analyse the results of a diagnostics protocol of Anal Intraepithelial Neoplasia in high risk population using anal cytology.
  • PATIENTS AND METHOD: The protocol is based on a visit in the outpatient department, clinical interview, physical examination and anal cytology evaluated by Bethesda criteria.
  • The cross-sectional observational study was designed to study the anal smear results and their relationship with risk factors.
  • In the overall series, 25 patients have been diagnosed with abnormal anal cytology: 9 atypical squamous cells of undetermined significance (ASCUS), 15 low-grade and 1 high-grade squamous intraepithelial lesions.
  • There were no significant associations between abnormal cytology results and the presence of anal condyloma (p = 0.22).
  • CONCLUSIONS: Our diagnostic protocol of anal intraepithelial neoplasia revealed 25% of patients with pre-invasive lesions of squamous anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303590.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


30. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S: Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer; 2010 Dec 07;103(12):1858-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.
  • BACKGROUND: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC).
  • This systematic review examines current prognostic markers in SCC of the anus.
  • METHODS: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
  • CONCLUSIONS: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer.
  • [MeSH-major] Anus Neoplasms / mortality. Biomarkers, Tumor. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Angiogenesis. 2008;11(4):321-35 [18925424.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):45-55 [18506774.001]
  • [Cites] Pathol Oncol Res. 2008 Dec;14(4):345-54 [18493868.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(1):31-9 [19221643.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 May;37(5):544-56 [19233691.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1792(4):229-39 [19419697.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3725-32 [19458054.001]
  • [Cites] Curr Drug Targets. 2009 Jul;10(7):581-9 [19601762.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Adv Genet. 2009;67:1-27 [19914448.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6213-21 [19884544.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):361-8 [20010949.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Cancer Biol Ther. 2010 Jan;9(1):23-30 [19923884.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):618-35 [15234243.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1239-44 [15292923.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):782-5 [3367186.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1745-55 [20215558.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Dig Dis Sci. 2010 Apr;55(4):1098-105 [19399614.001]
  • [Cites] Head Neck Oncol. 2010;2:8 [20398256.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):24-35 [20530316.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Clin Chem. 2000 Mar;46(3):313-8 [10702516.001]
  • [Cites] J Surg Oncol. 2000 Jun;74(2):163-6 [10914829.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9 [11098307.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1768-72 [11100055.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Dec;19(4):471-5 [11277325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1355-8 [11677963.001]
  • [Cites] Nat Rev Neurosci. 2002 Jan;3(1):24-33 [11823802.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):1-14 [11880176.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] Med Oncol. 2003;20(3):221-31 [14514971.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6489-96 [14695153.001]
  • [Cites] Dis Colon Rectum. 1991 Feb;34(2):126-31 [1993409.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1251-7 [1650445.001]
  • [Cites] EMBO J. 1992 Mar;11(3):961-71 [1312467.001]
  • [Cites] Acta Oncol. 1992;31(3):333-5 [1622654.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):98-102 [7691975.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):697-709 [7881344.001]
  • [Cites] Cancer Metastasis Rev. 1995 Mar;14(1):3-15 [7606818.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1096-100 [7576999.001]
  • [Cites] Virchows Arch. 1996 May;428(2):85-9 [8925129.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):369-73 [8784470.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int Surg. 1997 Jul-Sep;82(3):275-9 [9372374.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1831-5 [9815570.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Acta Histochem. 2005;107(2):87-93 [15950051.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] BMC Med Res Methodol. 2007;7:10 [17302989.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):376-86 [18223558.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1264-73 [18349847.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):946-53 [18396036.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • (PMID = 21063399.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC3008609
  •  go-up   go-down


31. Kagawa R, Yamaguchi T, Furuta R: Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today; 2006;36(10):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
  • PURPOSE: To investigate the development of anal squamous cell carcinoma (SCC) and the expression patterns of human papillomavirus (HPV).
  • The expression patterns of HPV in the cancer cell nuclei was investigated by in situ hybridization (ISH) using HPV probes.
  • RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with anal SCC, suggesting that tumor DNA was preserved in these patients.
  • In two patients with carcinoma in situ (CIS), the cancer cells showed only a diffuse pattern (DP), and in two patients with invasive cancer, the cancer cell showed only an oligo-dot pattern (OP).
  • In one patient with lesions ranging from CIS to invasive cancer, the histologic features varied in each area, from DP to OP.
  • CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of anal SCC and suggest that the change in the genome occurs at the stage of microinvasive cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 2002 Mar 01;7:e77-84 [11861218.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Am J Surg Pathol. 1986 Jan;10(1):1-8 [3006523.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):8-11 [2163992.001]
  • [Cites] Nucleic Acids Res. 1988 Dec 9;16(23):11141-56 [3205741.001]
  • [Cites] Jpn J Cancer Res. 1991 May;82(5):524-31 [1648051.001]
  • [Cites] EMBO J. 1984 May;3(5):1151-7 [6329740.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 [6304740.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] World J Gastroenterol. 1998 Aug;4(4):298-302 [11819303.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1967-73 [1326398.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] Int J Cancer. 1983 Nov 15;32(5):563-5 [6315601.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1247-61 [15648945.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Obstet Gynecol. 2004 Oct;104(4):751-5 [15458897.001]
  • (PMID = 16998682.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


32. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer; 2005 Oct 1;104(7):1505-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.
  • The most frequent NADCs were skin carcinomas (basal cell and squamous cell), Hodgkin disease, and anal carcinoma.
  • The results showed that there were higher rates of melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.
  • Melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals.


33. Fesneau M, Champeaux-Orange E, Hennequin C: [Anal cancer]. Cancer Radiother; 2010 Nov;14 Suppl 1:S120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer].
  • [Transliterated title] Cancer du canal anal.
  • Anal canal epidermoid carcinomas represent 1.2% of digestive cancers and 6% of ano-rectal cancers.
  • The recommended treatment dose is 45 Gy in the anal canal, the mesorectum, pararectal lymph nodes, and inguinal lymph nodes.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21129654.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Botelho M, Oliveira P, Gomes J, Gartner F, Lopes C, da Costa JM, Machado JC: Tumourigenic effect of Schistosoma haematobium total antigen in mammalian cells. Int J Exp Pathol; 2009 Aug;90(4):448-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schistosoma haematobium is endemic in several regions of Africa and has been shown to be associated with predominantly squamous cell bladder carcinoma.
  • The mechanisms underlying the association between S. haematobium and bladder squamous cell carcinoma is largely unknown.
  • All the reports so far, demonstrate exclusively an epidemiological evidence linking S. haematobium infection with squamous cell bladder carcinoma.
  • [MeSH-major] Antigens, Helminth / pharmacology. Carcinoma, Squamous Cell / microbiology. Schistosoma haematobium / pathogenicity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Parasitol. 2001 Apr;17(4):172-5 [11282506.001]
  • [Cites] Urol Int. 2008;80(1):90-7 [18204241.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1268-74 [15154012.001]
  • [Cites] Infect Immun. 1982 Oct;38(1):103-8 [6890530.001]
  • [Cites] Ciba Found Symp. 1983;99:190-206 [6557014.001]
  • [Cites] J Immunol. 1986 Feb 1;136(3):1100-6 [3510253.001]
  • [Cites] Histochem J. 1986 Jan;18(1):5-14 [2423479.001]
  • [Cites] Am J Trop Med Hyg. 1986 Nov;35(6):1185-91 [3098125.001]
  • [Cites] J Immunol. 1990 Jan 1;144(1):317-22 [2153167.001]
  • [Cites] Pathol Res Pract. 1989 Dec;185(6):878-85 [2616372.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Aug;14(4):312-9 [1388568.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1485-9 [9276620.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jan;49(1):17-20 [16625965.001]
  • [Cites] BMC Gastroenterol. 2006;6:13 [16584555.001]
  • [Cites] Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):133-8 [11388504.001]
  • (PMID = 19659903.001).
  • [ISSN] 1365-2613
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  • [Other-IDs] NLM/ PMC2741155
  •  go-up   go-down


37. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • METHODS: Retrospective review of 246 patients with high-grade squamous intraepithelial lesions treated with high-resolution anoscopy-targeted surgical destruction from 1996 to 2006, with at least one follow-up at a minimum two months with physical examination, high-resolution anoscopy, cytology, and biopsy when indicated.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • At their last visit, 192 patients (78 percent) had no evidence of high-grade squamous intraepithelial lesions.
  • CONCLUSIONS: High-resolution anoscopy-targeted destruction combined with office-based surveillance and therapy is effective in controlling high-grade squamous intraepithelial lesions and is superior to reports of expectant management or traditional mapping procedures.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • Biopsies of the border of the perianal plaque also revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • Histological analysis on the excised tissue revealed high-grade squamous intraepithelial lesion with one focus of microinvasive squamous cell cancer measuring 1 mm.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


39. Seth A, Agarwal A: Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study. J Lab Physicians; 2009 Jan;1(1):11-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study.
  • AIMS: The study aims to find out if a correlation between apoptotic count and histological grading exists in squamous cell carcinoma of the esophagus, and also to review the literature on such a relationship in the context of some other tumors.
  • SETTINGS AND DESIGN: Cases of squamous cell carcinoma of the esophagus who presented at a tertiary care center over a period of one year were reviewed.
  • MATERIALS AND METHODS: The endoscopic biopsy specimens of 56 patients of squamous cell carcinoma of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece.
  • CONCLUSIONS: Grading of squamous cell carcinoma of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2123-8 [10928164.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):88-101 [8990145.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Jul;44(3):257-9 [12024908.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1036-44 [17643097.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Stroke. 1995 Jul;26(7):1252-7; discussion 1257-8 [7541573.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):826-31 [7790118.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jan;121(1):54-8 [9111093.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):901-11 [9265655.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Apr;24(2):73-80 [12026053.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Dec;34(8):900-6 [15907374.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):19-20 [8538735.001]
  • [Cites] Histopathology. 1995 Nov;27(5):469-72 [8575739.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2470-5 [8630413.001]
  • [Cites] Indian J Pathol Microbiol. 2000 Jul;43(3):271-5 [11218671.001]
  • (PMID = 21938242.001).
  • [ISSN] 0974-2727
  • [Journal-full-title] Journal of laboratory physicians
  • [ISO-abbreviation] J Lab Physicians
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167958
  • [Keywords] NOTNLM ; Apoptotic count / histological grading / squamous cell carcinoma esophagus
  •  go-up   go-down


40. Aboumarzouk OM, Coleman R, Goepel JR, Shorthouse AJ: PNET/Ewing's sarcoma of the rectum: a case report and review of the literature. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A trephine loop ileostomy was fashioned and biopsies were initially reported to show a poorly differentiated cloacogenic carcinoma.
  • Serial CT scanning and endoscopy revealed no recurrence after 7 years of follow-up, when she presented with a malignant anal fissure.
  • Imaging and subsequently abdominoperineal resection revealed no evidence of metastases from either the anal cancer or the PNET tumour.
  • Histopathology showed a T1N0R0 basaloid squamous carcinoma originating from grade III squamous intraepithelial neoplasia with no obvious wart viral infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2006 Jul;37(7):845-53 [16784984.001]
  • [Cites] MedGenMed. 2006;8(3):6 [17406148.001]
  • [Cites] Clin Imaging. 1993 Apr-Jun;17(2):149-52 [8348407.001]
  • [Cites] Cancer. 1973 Oct;32(4):890-7 [4751919.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):427-32 [17572479.001]
  • [Cites] Acta Oncol. 2006;45(4):484-6 [16760186.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):910-2 [15681537.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Sep-Oct;22(5):391-8 [14692190.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):345-6 [12400989.001]
  • [Cites] Cancer. 1975 Jul;36(1):240-51 [1203852.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1358-60 [11570916.001]
  • [Cites] Radiology. 1969 Jun;92(7):1501-9 [5799839.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):648-54 [2065287.001]
  • [Cites] Ann Thorac Surg. 2004 Aug;78(2):715-7 [15276562.001]
  • (PMID = 21691396.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029497
  •  go-up   go-down


41. Poeta ML, Manola J, Goldenberg D, Forastiere A, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM: The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clin Cancer Res; 2009 Dec 15;15(24):7658-7665
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins.
  • EXPERIMENTAL DESIGN: Patients with head and neck cancer were registered for molecular analysis of surgical margins.
  • Cutpoints were identified and defined groups were evaluated for local failure-free, cancer-specific, and overall survival.
  • No statistically significant distinctions were observed in cancer-specific or overall survival in this limited cohort.
  • Detection of mutant species in margins may identify patients at risk of local recurrence. (Clin Cancer Res 2009;15(24):7658-65).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996217.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027525; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA066636; United States / NIDCR NIH HHS / DE / DE013152-09; United States / NCI NIH HHS / CA / U10 CA016116; United States / NIDCR NIH HHS / DE / R01 DE013152; United States / NCI NIH HHS / CA / U10 CA023318; United States / NIDCR NIH HHS / DE / DE013152-08; United States / NIDCR NIH HHS / DE / DE013152-10A1; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


42. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Mol Cell Biochem. 2009 Dec;332(1-2):51-8 [19513816.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1331-5 [1499084.001]
  • [Cites] Curr Opin Oncol. 1993 Jan;5(1):123-9 [8427884.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):347-9 [8673135.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2578-80 [9205057.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):2033-7 [10208426.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):62-8 [15761872.001]
  • [Cites] Am Surg. 2005 Apr;71(4):336-43 [15943410.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] Int J Biol Sci. 2010;6(1):1-8 [20087440.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Bioessays. 2001 Mar;23(3):223-32 [11223879.001]
  • [Cites] Ann Agric Environ Med. 2001;8(1):1-5 [11426918.001]
  • [Cites] Genome Biol. 2001;2(8):REVIEWS3010 [11532220.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80 [12198585.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):387-93 [14506738.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Exp Oncol. 2004 Jun;26(2):98-105 [15273660.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 [3056609.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Mutat Res. 2009 May 31;676(1-2):5-10 [19486858.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):219-25 [19574674.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Indian J Pathol Microbiol. 1990 Apr;33(2):118-23 [2391141.001]
  • (PMID = 20565773.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2927996
  •  go-up   go-down


43. Esquibies AE, Zambrano E, Ziai J, Kesebir D, Touloukian RJ, Egan ME, Reyes-Múgica M, Bazzy-Asaad A: Pulmonary squamous cell carcinoma associated with repaired congenital tracheoesophageal fistula and esophageal atresia. Pediatr Pulmonol; 2010 Feb;45(2):202-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary squamous cell carcinoma associated with repaired congenital tracheoesophageal fistula and esophageal atresia.
  • We report a 19-year-old man with pulmonary squamous cell carcinoma (SCC) who had a history of vertebral, anal, cardiac, tracheal, esophageal, renal, and radial limb defects (VACTERL) association and tracheoesophageal fistula (TEF) + esophageal atresia (EA) repair as an infant.
  • Children that undergo TEF + EA repair may have an increased risk for developing cancer as they reach adulthood.
  • [MeSH-major] Abnormalities, Multiple / surgery. Carcinoma, Squamous Cell / etiology. Esophageal Atresia / surgery. Lung Neoplasms / etiology. Postoperative Complications / etiology. Tracheoesophageal Fistula / surgery


44. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


45. Neppelberg E, Johannessen AC: DNA content, Cyclooxygenase-2 expression and loss of E-cadherin expression do not predict risk of malignant transformation in oral lichen planus. Eur Arch Otorhinolaryngol; 2007 Oct;264(10):1223-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) 26 OLP patients with at least two biopsies, of whom seven presented OLP with epithelial dysplasia, followed by oral squamous cell carcinoma (OSCC) in five of them, (2) 19 OLP patients with one biopsy taken.

  • Genetic Alliance. consumer health - Oral lichen planus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2004 Mar;9(2):123-30 [15004509.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Sep;88(3):307-10 [10503859.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):131-8 [14693235.001]
  • [Cites] J Oral Pathol. 1978 Feb;7(1):1-7 [418159.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Jan;79(1):68-76 [7614165.001]
  • [Cites] Oral Oncol. 2006 Feb;42(2):190-200 [16249116.001]
  • [Cites] Int J Biochem Cell Biol. 1999 May;31(5):551-7 [10399316.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):304-12 [15743693.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Oct;28(5):262-8 [17067008.001]
  • [Cites] Eur Surg Res. 1998;30(6):385-92 [9838230.001]
  • [Cites] Gut. 2002 Jan;50(1):84-9 [11772972.001]
  • [Cites] Gut. 2000 Jun;46(6):782-9 [10807888.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Mar;89(3):265-6 [10710445.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):164-78 [16037774.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78 [10722929.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Oct;26(5):278-84 [15560534.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1227-35 [16729014.001]
  • [Cites] Biochem J. 1999 Jun 15;340 ( Pt 3):621-30 [10359645.001]
  • [Cites] Anal Quant Cytol Histol. 1991 Feb;13(1):7-10 [1851011.001]
  • [Cites] J Oral Maxillofac Surg. 2000 Nov;58(11):1278-85 [11078140.001]
  • [Cites] IUBMB Life. 2004 Feb;56(2):65-81 [15085930.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] Oral Oncol. 2004 Jan;40(1):77-83 [14662419.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):12-22 [16331679.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(1):47-62 [12764019.001]
  • [Cites] Bioessays. 2004 May;26(5):497-511 [15112230.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1993 Oct;29B(4):303-5 [11706426.001]
  • [Cites] Acta Oncol. 1987;26(5):349-55 [3426846.001]
  • [Cites] J Oral Pathol Med. 2006 Apr;35(4):227-32 [16519770.001]
  • [Cites] Head Neck. 2002 Aug;24(8):792-9 [12203806.001]
  • [Cites] Histopathology. 2004 Apr;44(4):353-9 [15049901.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):190-6 [10662596.001]
  • [Cites] Med Hypotheses. 2001 Jan;56(1):58-64 [11133256.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Carcinogenesis. 2006 Feb;27(2):337-43 [16123119.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5930-9 [15355926.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):73-6 [10098402.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Sep;60(3):308-15 [3862044.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2005 Apr 01;10 Suppl 1:E9-14 [15800471.001]
  • [Cites] J Oral Pathol Med. 2007 Mar;36(3):153-60 [17305637.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6323-8 [12414664.001]
  • [Cites] Crit Rev Oral Biol Med. 2002;13(5):390-6 [12393758.001]
  • (PMID = 17530268.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


46. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S: Immune suppression in head and neck cancers: a review. Clin Dev Immunol; 2010;2010:701657
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancer in the world.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Head and Neck Neoplasms / immunology. Tumor Escape

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9281-9 [16982773.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):705-13 [16864600.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1061-73 [17122156.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4409-13 [17201162.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5069-75 [12208763.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):350-5 [19383307.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):75-81 [12495737.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):882-8 [12925349.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6478-87 [14559840.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):69-76 [14657228.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):267-72 [14719133.001]
  • [Cites] Int J Exp Pathol. 2003 Dec;84(6):259-65 [14748745.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5101-10 [15297413.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):25-33 [18298326.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):11-8 [18308558.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1133-8 [18505048.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3706-15 [18559587.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):27-33 [1734363.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):100-4 [1374796.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):92-6 [8501912.001]
  • [Cites] J Oral Pathol Med. 1994 Feb;23(2):55-9 [8164153.001]
  • [Cites] In Vivo. 1994 Jul-Aug;8(4):543-7 [7893981.001]
  • [Cites] In Vivo. 1995 May-Jun;9(3):225-9 [8562888.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):436-40 [8630949.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):333-8 [8707405.001]
  • [Cites] Crit Rev Oral Biol Med. 1996;7(1):36-58 [8727106.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):830-2 [8749207.001]
  • [Cites] Curr Opin Immunol. 1997 Feb;9(1):10-6 [9039784.001]
  • [Cites] Mod Pathol. 1997 Nov;10(11):1128-33 [9388064.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Immunother. 1998 Jul;21(4):295-306 [9672851.001]
  • [Cites] J Cutan Pathol. 1998 Oct;25(9):463-8 [9821075.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Acta Otolaryngol. 1999;119(6):732-8 [10587010.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2065-6 [10601369.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1219-23 [12375023.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):617-22 [17262084.001]
  • [Cites] J Cell Physiol. 2007 May;211(2):273-8 [17311299.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Feb;29(1):57-62 [17375875.001]
  • [Cites] Head Neck. 2010 Jul;32(7):946-58 [20191626.001]
  • [Cites] J Cancer Res Clin Oncol. 2011 Jan;137(1):173-81 [20376678.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2015-23 [10706869.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2794-802 [10914726.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1213-22 [11067871.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6811-7 [11156370.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2136-47 [11391595.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):781-5 [11519037.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):43-50 [11926411.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):545-57 [12014622.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1787-93 [12060618.001]
  • [Cites] Clin Exp Metastasis. 2002;19(3):247-58 [12067205.001]
  • [Cites] Histopathology. 2002 Aug;41(2):152-7 [12147093.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5344-7 [9850063.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1111-6 [9849463.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):329-34 [10037182.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(2):83-8 [10202560.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1263-73 [10389908.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3468-74 [10416612.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(6):299-302 [10456279.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):346-52 [10501846.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(8):384-7 [10525939.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8126-9 [15520225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):573-6 [15523428.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75 [15545580.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1984-91 [16284959.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3402-9 [16517708.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Head Neck. 2006 May;28(5):462-70 [16284974.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3890-5 [16818683.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1833-48 [16827115.001]
  • [Cites] Immunol Rev. 2006 Aug;212:314-29 [16903923.001]
  • [Cites] Oral Dis. 2006 Sep;12(5):455-62 [16910915.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1137-46 [17476343.001]
  • [Cites] Cancer Immunol Immunother. 2007 Sep;56(9):1429-42 [17265021.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):977-83 [17617589.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54 [17671115.001]
  • [Cites] Acta Otolaryngol. 2007 Sep;127(9):980-7 [17712679.001]
  • [Cites] Head Neck. 2007 Sep;29(9):874-84 [17315170.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6301-11 [17975141.001]
  • [Cites] Head Neck. 2008 Feb;30(2):251-61 [18172882.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):527-35 [18292929.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):277-85 [17475541.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Feb;132(2):309-16 [15692546.001]
  • [Cites] Cancer Immunol Immunother. 2004 Dec;53(12):1055-67 [15095020.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1010-20 [15709166.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):522-7 [15744170.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):913-20 [15714205.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jan;24(1):95-105 [15785875.001]
  • [Cites] Semin Immunol. 2005 Aug;17(4):273-83 [15953735.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3045-52 [16116192.001]
  • [Cites] Med Sci Monit. 2005 Aug;11(8):BR280-92 [16049374.001]
  • [Cites] Immunol Res. 2005;33(2):113-33 [16234579.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1337-44 [16303684.001]
  • [Cites] Cell Oncol. 2005;27(4):203-13 [16308469.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11146-55 [16322265.001]
  • [Cites] Swed Dent J Suppl. 2005;(179):1-66 [16335030.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Nov;262(11):917-20 [15924277.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):183-93 [16125469.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1123-31 [16424049.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):465-72 [16428488.001]
  • [Cites] Oral Oncol. 2008 Jul;44(7):672-82 [17996489.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3128-37 [18474878.001]
  • [Cites] Ann Diagn Pathol. 2008 Oct;12(5):322-7 [18774493.001]
  • [Cites] J Oral Pathol Med. 2008 Sep;37(8):485-9 [18355177.001]
  • [Cites] Crit Rev Immunol. 2008;28(3):201-13 [19024345.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]
  • [Cites] J Immunol. 2009 Feb 1;182(3):1469-80 [19155494.001]
  • [Cites] Head Neck. 2009 Mar;31(3):318-27 [19072995.001]
  • [Cites] Head Neck. 2009 Mar;31(3):371-80 [19073006.001]
  • [Cites] J Craniofac Surg. 2009 Mar;20(2):287-9 [19218858.001]
  • [Cites] J Otolaryngol Head Neck Surg. 2009 Feb;38(1):119-25 [19344621.001]
  • [Cites] Hum Immunol. 2009 May;70(5):289-93 [19217922.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] Immunol Lett. 2009 Apr 27;123(2):97-102 [19428556.001]
  • [Cites] Int J Surg Pathol. 2009 Jun;17(3):244-9 [19443887.001]
  • [Cites] J Laryngol Otol Suppl. 2009;(31):5-10 [19460197.001]
  • [Cites] Head Neck. 2009 Jul;31(7):911-8 [19283850.001]
  • [Cites] Cancer Epidemiol. 2009 Aug;33(2):118-22 [19679058.001]
  • [Cites] Biochim Biophys Acta. 2009 Aug;1796(1):11-8 [19269310.001]
  • [Cites] Oral Oncol. 2009 Oct;45(10):e167-74 [19576838.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6348-57 [19825957.001]
  • [Cites] Indian J Med Res. 2009 Sep;130(3):266-76 [19901436.001]
  • [Cites] Immunology. 2009 Nov;128(3):439-50 [20067543.001]
  • [Cites] Eur J Dermatol. 2010 Jan-Feb;20(1):16-23 [19850548.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2010 Mar;267(3):335-44 [19967383.001]
  • [Cites] Mol Cancer. 2010;9:4 [20064222.001]
  • [Cites] Immunol Rev. 2010 Mar;234(1):45-54 [20193011.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Mar;3(3):266-78 [20179299.001]
  • [Cites] Cell. 2010 Apr 2;141(1):39-51 [20371344.001]
  • [Cites] J Med Virol. 2010 May;82(6):1017-23 [20419817.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Oral Pathol Med. 1991 Feb;20(2):49-52 [2016696.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Sep;117(9):1007-10 [1910715.001]
  • (PMID = 21437225.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC3061296
  •  go-up   go-down


47. French JT, Goins B, Saenz M, Li S, Garcia-Rojas X, Phillips WT, Otto RA, Bao A: Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol; 2010 Aug;21(8):1271-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.
  • PURPOSE: Minimally invasive interventional cancer therapy with drug-carrying lipid nanoparticles (ie, liposomes) via convection-enhanced delivery by an infusion pump can increase intratumoral drug concentration and retention while facilitating broad distribution throughout solid tumors.
  • The authors investigated the utility of liposome-carrying beta-emitting radionuclides to treat head and neck cancer by direct intratumoral infusion in nude rats.
  • MATERIALS AND METHODS: Four groups of nude rats were subcutaneously inoculated with human tongue cancer cells.
  • CONCLUSIONS: Liposomal (186)Re effectively treated head and neck cancer with minimal side effects after convection-enhanced interventional delivery.
  • These results suggest the potential of liposomal (186)Re for clinical application in interventional therapy of cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 SIR. Published by Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10007-20 [19074862.001]
  • [Cites] Ann Nucl Med. 2008 Oct;22(8):653-60 [18982467.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):571-82 [19083000.001]
  • [Cites] ACS Nano. 2009 Jan 27;3(1):16-20 [19206243.001]
  • [Cites] Cancer Gene Ther. 2009 Mar;16(3):217-26 [18927599.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4324-7 [10969769.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):243-54 [11234875.001]
  • [Cites] Eur J Nucl Med. 2001 May;28(5):567-9 [11383859.001]
  • [Cites] J Pharm Sci. 2003 Sep;92(9):1893-904 [12950007.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1992-9 [14660726.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Feb;308(2):419-25 [14610219.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):500-7 [15001694.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):647-51 [15483337.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):10-4 [6892980.001]
  • [Cites] J Nucl Med. 1989 Jun;30(6):1036-46 [2738686.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):265-73 [1988088.001]
  • [Cites] Phys Med Biol. 1996 Oct;41(10):1905-14 [8912370.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):980-7 [10091778.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):931-5 [10489968.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):145-60 [15688077.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):117-34 [15761080.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):514-20 [16053871.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E12 [16709017.001]
  • [Cites] Int J Pharm. 2006 Jun 19;316(1-2):162-9 [16580161.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jun;3(6):315-24 [16757969.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):853-7 [17141073.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3975-83 [18559620.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Jul;134(7):735-42 [18645124.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):8-17 [18992016.001]
  • (PMID = 20478719.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA131039-01A2; United States / NCI NIH HHS / CA / R01 CA131039; United States / NCI NIH HHS / CA / R01 CA131039-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids; 0 / Liposomes; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 14333-24-5 / perrhenate; 7440-15-5 / Rhenium
  • [Other-IDs] NLM/ NIHMS187673; NLM/ PMC2910224
  •  go-up   go-down


48. Kähler D, Alexander C, Schultz H, Abdullah M, Branscheid D, Lindner B, Zabel P, Vollmer E, Goldmann T: Proteomics out of the archive: Two-dimensional electrophoresis and mass spectrometry using HOPE-fixed, paraffin-embedded tissues. J Histochem Cytochem; 2010 Mar;58(3):221-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that HOPE fixation is also useful in proteomic investigations by allowing two-dimensional electrophoresis (2DE) and mass spectrometry, using lung cancer tissues.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Proteome / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Histochem. 2000 Feb;102(1):5-14 [10726160.001]
  • [Cites] J Histochem Cytochem. 2009 Sep;57(9):849-60 [19471015.001]
  • [Cites] Pathol Res Pract. 2001;197(12):823-6 [11795830.001]
  • [Cites] Proteomics. 2001 Nov;1(11):1359-63 [11922595.001]
  • [Cites] Pathol Res Pract. 2002;198(2):91-5 [11928870.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):286-93 [12031084.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Pathol Res Pract. 2002;198(11):735-40 [12530576.001]
  • [Cites] Histochem Cell Biol. 2003 Feb;119(2):103-8 [12610729.001]
  • [Cites] Proteomics. 2003 Apr;3(4):413-21 [12687609.001]
  • [Cites] J Histochem Cytochem. 2003 Jul;51(7):977-80 [12810849.001]
  • [Cites] Pathol Res Pract. 2003;199(9):619-23 [14621198.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2638-40 [14633636.001]
  • [Cites] Pathol Res Pract. 2004;200(6):469-72 [15310150.001]
  • [Cites] Pathol Res Pract. 2004;200(7-8):511-5 [15462498.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2724-9 [2452011.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Cancer Lett. 1997 Dec 16;121(1):31-7 [9459171.001]
  • [Cites] Diagn Mol Pathol. 2006 Jun;15(2):115-23 [16778593.001]
  • [Cites] J Mol Med (Berl). 2007 Aug;85(8):863-75 [17318615.001]
  • [Cites] Cesk Patol. 1999 Jul;35(3):80-4 [11038661.001]
  • (PMID = 19995946.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Proteome; 1HG84L3525 / Formaldehyde; 3K9958V90M / Ethanol
  • [Other-IDs] NLM/ PMC2825487
  •  go-up   go-down


49. Hu W, Xu R, Sun W, Szulc ZM, Bielawski J, Obeid LM, Mao C: Alkaline ceramidase 3 (ACER3) hydrolyzes unsaturated long-chain ceramides, and its down-regulation inhibits both cell proliferation and apoptosis. J Biol Chem; 2010 Mar 12;285(11):7964-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Carcinoma, Squamous Cell / pathology. Cell Division / physiology. Culture Media, Serum-Free / pharmacology. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Down-Regulation / physiology. Gene Expression Regulation, Enzymologic. HeLa Cells. Humans. Hydrolysis. Keratinocytes / cytology. Keratinocytes / enzymology. Muscle, Smooth, Vascular / cytology. Muscle, Smooth, Vascular / enzymology. RNA, Messenger / metabolism. RNA, Small Interfering. Skin Neoplasms / pathology. Substrate Specificity. Umbilical Veins / cytology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2001 Jan;15(1):123-133 [11149900.001]
  • [Cites] Biochem J. 1982 Aug 1;205(2):419-25 [6814427.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31369-78 [10900202.001]
  • [Cites] Subcell Biochem. 2002;36:187-205 [12037981.001]
  • [Cites] Pharmacol Res. 2003 May;47(5):439-45 [12676517.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23722-8 [9726979.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6876-84 [10702247.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26577-88 [11356846.001]
  • [Cites] Chem Phys Lipids. 2008 May;153(1):57-63 [18343224.001]
  • [Cites] Methods. 2006 Jun;39(2):82-91 [16828308.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1758(12):1864-84 [17052686.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):33110-5 [8955159.001]
  • [Cites] Biochim Biophys Acta. 1988 Mar 25;959(2):185-96 [3349097.001]
  • [Cites] J Biol Chem. 2006 Sep 1;281(35):25001-5 [16793762.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Feb;61(2):231-42 [17429631.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31184-91 [12783875.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3618-30 [11694593.001]
  • [Cites] Cell Death Differ. 2007 Oct;14(10):1780-91 [17627285.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12960-9 [11815611.001]
  • [Cites] Anal Biochem. 1988 Jun;171(2):373-81 [3407935.001]
  • [Cites] Trends Endocrinol Metab. 2007 Oct;18(8):300-7 [17904858.001]
  • [Cites] Biochemistry. 2001 Aug 14;40(32):9657-68 [11583166.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1781(9):424-34 [18619555.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):444-50 [11391861.001]
  • [Cites] Cell Death Differ. 1998 May;5(5):381-9 [10200487.001]
  • [Cites] Biochem J. 2005 Feb 1;385(Pt 3):685-93 [15361069.001]
  • [Cites] Neurochem Int. 2002 Apr;40(4):327-36 [11792463.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1129-34 [17373752.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21508-13 [10781606.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):19513-20 [10751414.001]
  • [Cites] Pediatr Rheumatol Online J. 2007 Jun 29;5:15 [17603888.001]
  • [Cites] Biochim Biophys Acta. 2009 Aug;1791(8):730-9 [19345744.001]
  • [Cites] FASEB J. 2006 Sep;20(11):1813-25 [16940153.001]
  • [Cites] Can J Biochem Physiol. 1959 Aug;37(8):911-7 [13671378.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 30;1585(2-3):153-62 [12531549.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):18141-50 [17392276.001]
  • [Cites] Biotechniques. 2002 Jun;32(6):1372-4, 1376, 1378-9 [12074169.001]
  • [Cites] Biochim Biophys Acta. 1982 Oct 8;718(2):185-92 [6814495.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 27;331(1):37-42 [15845354.001]
  • [Cites] J Biol Chem. 1999 Sep 24;274(39):27948-55 [10488143.001]
  • [Cites] Toxicol In Vitro. 2002 Aug;16(4):349-55 [12110272.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):263-71 [15823095.001]
  • [Cites] J Invest Dermatol. 2008 Feb;128(2):389-97 [17713573.001]
  • (PMID = 20068046.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR017677; United States / NIGMS NIH HHS / GM / R01GM062887; United States / NCI NIH HHS / CA / R01CA104834; United States / NIGMS NIH HHS / GM / R01 GM062887; United States / NCI NIH HHS / CA / R01 CA104834; United States / NCRR NIH HHS / RR / P20 RR017677
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Ceramides; 0 / Culture Media, Serum-Free; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / dihydroceramide; EC 3.5.1.23 / ACER3 protein, human; EC 3.5.1.23 / Alkaline Ceramidase; EC 3.5.1.23 / Ceramidases
  • [Other-IDs] NLM/ PMC2832947
  •  go-up   go-down


50. Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S, Sato F, Martorell M, Garcia JA, Perez A, Shimada Y: Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol; 2010;5:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines.
  • Fascin overexpression was associated with poor prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma (ESCC).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carrier Proteins / genetics. Esophageal Neoplasms / genetics. Microfilament Proteins / genetics. RNA Interference. RNA, Small Interfering / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] Thyroid. 2009 Jul;19(7):735-42 [19485776.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):421-5 [15157151.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(4):1254-8 [2919174.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9115-9 [8415664.001]
  • [Cites] Biotechniques. 1993 Sep;15(3):532-4, 536-7 [7692896.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):249-56 [10806474.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4864-75 [11039904.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):338-45 [11123310.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G75-87 [11123200.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 Feb;48(2):109-20 [11169763.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):987-91 [11956233.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):243-9 [12538476.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):1-7 [12689665.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Curr Opin Cell Biol. 1994 Feb;6(1):105-9 [8167015.001]
  • [Cites] Semin Cell Biol. 1994 Jun;5(3):165-74 [7919230.001]
  • [Cites] J Virol. 1994 Nov;68(11):7320-8 [7933116.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2752-5 [7796399.001]
  • [Cites] Ann Surg Oncol. 1996 Jan;3(1):100-5 [8770310.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):218-23 [10468791.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5487-94 [16707478.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5267-75 [17122112.001]
  • [Cites] J Biomed Sci. 2009;16:100 [19917110.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):761-71 [17113264.001]
  • [Cites] Apoptosis. 2007 Dec;12(12):2221-31 [17879163.001]
  • [Cites] Oncogene. 2007 Nov 8;26(51):7194-203 [17525740.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):174-80 [18835624.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • (PMID = 20565981.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Carrier Proteins; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / RNA, Small Interfering; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 146808-54-0 / fascin; 9007-34-5 / Collagen; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2907320
  •  go-up   go-down


51. Ascani G, Balercia P, Messi M, Lupi L, Goteri G, Filosa A, Stramazzotti D, Pieramici T, Rubini C: Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):13-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in oral squamous cell carcinoma.
  • Based on these results, microvessel density was evaluated, in the present study, in 64 cases of squamous cell carcinoma of the oral cavity, using immunohistochemical analysis with anti-CD34 monoclonal antibody.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):183-92 [11564894.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Dec;20(4):463-8 [11876537.001]
  • [Cites] Head Neck. 2002 Jul;24(7):643-50 [12112537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jan;33(1):2-7 [14690652.001]
  • [Cites] Sci Am. 1976 May;234(5):58-64, 70-3 [1273568.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Eur J Cancer. 1993;29A(8):1141-5 [8390846.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):678-87 [7507798.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Oct;111(4):417-22 [7524005.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):373-80 [7526718.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008 [7543156.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1417-22 [7544566.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Feb;34(1):37-41 [8645680.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):865-8 [8703391.001]
  • [Cites] Head Neck. 1996 Jul-Aug;18(4):343-6 [8780945.001]
  • [Cites] Head Neck. 1997 Jul;19(4):276-80 [9213105.001]
  • [Cites] J Pathol. 1997 Sep;183(1):39-43 [9370945.001]
  • [Cites] Oral Oncol. 1997 Sep;33(5):369-74 [9415339.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):659-64 [9426404.001]
  • [Cites] Annu Rev Med. 1998;49:407-24 [9509272.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2821-8 [10914730.001]
  • (PMID = 16080310.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD31
  • [Other-IDs] NLM/ PMC2639850
  •  go-up   go-down


52. Groseclose MR, Massion PP, Chaurand P, Caprioli RM: High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics; 2008 Sep;8(18):3715-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A TMA section containing 112 needle core biopsies from lung-tumor patients was analyzed using MS and the data were correlated to a serial hematoxylin and eosin (H&E)-stained section having various histological regions marked, including cancer, non-cancer, and normal ones.
  • By correlating each mass spectrum to a defined histological region, statistical classification models were generated that can sufficiently distinguish biopsies from adenocarcinoma from squamous cell carcinoma biopsies.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1985 Aug;33(8):845-53 [3894502.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Lab Invest. 1990 Nov;63(5):722-4 [2232717.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Toxicol Pathol. 2005;33(1):92-101 [15805060.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Lab Invest. 2005 Nov;85(11):1405-15 [16155593.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1741-53 [16091476.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10642-5 [16322204.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 15;172(12):1556-62 [16179643.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2404-11 [16335994.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):809-19 [16448055.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):827-34 [16448057.001]
  • [Cites] J Histochem Cytochem. 2006 Jun;54(6):739-43 [16399996.001]
  • [Cites] J Mass Spectrom. 2006 Jun;41(6):705-16 [16718638.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1975-83 [16849436.001]
  • [Cites] Anal Chem. 2006 Oct 15;78(20):7145-53 [17037914.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2889-900 [17081040.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):65-76 [16799640.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1038-47 [17266348.001]
  • [Cites] J Mass Spectrom. 2007 Feb;42(2):254-62 [17230433.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1295-305 [17291023.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):828-33 [17901873.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4127-34 [17939699.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Gen Intern Med. 2008 Jan;23 Suppl 1:78-84 [18095050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Proteomics. 2003 Apr;3(4):413-21 [12687609.001]
  • [Cites] J Mass Spectrom. 2003 Jul;38(7):699-708 [12898649.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):190-9 [14983931.001]
  • [Cites] Lab Invest. 1986 Aug;55(2):244-8 [3525985.001]
  • (PMID = 18712763.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NCI NIH HHS / CA / R01 CA102353; United States / NIGMS NIH HHS / GM / 5R01GM58008-08D; United States / NIGMS NIH HHS / GM / R01 GM058008-10; United States / NIGMS NIH HHS / GM / GM058008-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ NIHMS227070; NLM/ PMC2927989
  •  go-up   go-down


53. Chan E, Kachnic LA, Thomas CR Jr: Anal cancer: progress on combined-modality and organ preservation. Curr Probl Cancer; 2009 Sep-Oct;33(5):302-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: progress on combined-modality and organ preservation.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy / trends. Proctoscopy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082844.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


54. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Gedoz L, Bohrer PL, Paiva RL, Burzlaff JB, Rösing CK, Sant'Ana Filho M, Rados PV: Validation of cytopathology as a technique for analysis of epithelial cell maturation in oral mucosa of smokers and nonsmokers. Anal Quant Cytol Histol; 2009 Apr;31(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Sixty samples from the oral mucosa of 10 smokers and 10 nonsmokers were collected from the anatomic sites more frequently affected by oral cancer: lower lip, border of the tongue and floor of the mouth.
  • Slides were stained using Papanicolau and Traut techniques; anucleated squamous, nucleated superficial and intermediate cells were counted.

  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402386.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


56. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg; 2010 Apr;139(4):984-90; discussion 990
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.
  • OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC).
  • METHODS: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics.
  • For example MMP-1, -8, -9, and -12 increased by more than 4-fold in squamous cell versus adenocarcinoma (P < .05).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):45-56 [16680571.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):941-6 [16538215.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5448-53 [17000679.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2054-60 [17404086.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1362-78 [18258475.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1188-94 [18422740.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2185-92 [18823373.001]
  • [Cites] Ann Thorac Surg. 2008 Nov;86(5):1576-83 [19049753.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):67-74 [19331134.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):894-901 [19480010.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2513-7 [19596921.001]
  • [Cites] J Pathol. 2000 Feb;190(2):150-6 [10657012.001]
  • [Cites] Circulation. 2000 Oct 17;102(16):1944-9 [11034943.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):421-4 [11182067.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):647-51 [12494473.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):745-51 [12866035.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3098-104 [12912961.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):541-50 [14520690.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):171-9 [15246188.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):461-9 [9234385.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):149-53 [9918213.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1086-92 [15709175.001]
  • [Cites] Circulation. 2005 Mar 8;111(9):1166-74 [15723986.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1676-84 [15754326.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Anal Biochem. 2005 Aug 1;343(1):54-65 [15953581.001]
  • [Cites] Am J Cardiol. 2006 Feb 15;97(4):532-7 [16461051.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):313-21 [16423426.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I365-70 [16820601.001]
  • (PMID = 20304142.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL059165; United States / NHLBI NIH HHS / HL / R01 HL059165-11; United States / NHLBI NIH HHS / HL / HL59165; United States / NHLBI NIH HHS / HL / HL81691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS167053; NLM/ PMC2844342
  •  go-up   go-down


57. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A; 2007 Jan 16;104(3):973-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
  • Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells.
  • We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples.
  • We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo.
  • Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin.
  • Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1999;19(2):53-8 [10746434.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):601-2 [11207357.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Gene Ther. 2002 May;9(10):606-12 [12032706.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2256-9 [12215650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):175-9 [14722607.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86 [15375804.001]
  • [Cites] J Pathol. 1985 Apr;145(4):329-40 [3889247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 [1373493.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1579-89 [15897275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • (PMID = 17210912.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / 5P50 CA 097248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44
  • [Other-IDs] NLM/ PMC1783424
  •  go-up   go-down


58. Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh H, Hizawa N: Serum KL-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal; 2010;24(5):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.
  • BACKGROUND: It is not known whether lung cancer patients with interstitial lung disease (ILD) might have higher serum levels of KL-6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin.
  • METHODS: Serum KL-6 levels in 273 lung cancer patients with or without ILD, and prognostic significance of elevated serum KL-6 levels in these patients were studied using uni- and multivariate analyses.
  • RESULTS: Serum KL-6 levels were elevated (>500 U/ml) in 73.5% of lung cancer patients with ILD and in 33.7% of those without ILD.
  • Serum KL-6 levels in lung cancer patients with ILD were significantly higher than those without ILD.
  • In lung cancer patients with ILD, elevated serum KL-6 has no prognostic significance, but in those without ILD, however, it was one of the unfavorable prognostic factors.
  • CONCLUSIONS: Elevated serum KL-6 levels can be observed in lung cancer patients both with and without ILD.
  • Having ILD has strong prognostic impact in patients with lung cancer.
  • [MeSH-major] Adenocarcinoma / blood. Carcinoma, Large Cell / blood. Carcinoma, Small Cell / blood. Carcinoma, Squamous Cell / blood. Lung Diseases, Interstitial / blood. Lung Neoplasms / blood. Mucin-1 / blood


59. Maw MK, Fujimoto J, Tamaya T: Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer; 2008 Nov 18;99(10):1557-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Inhibitor of Differentiation Protein 1 / biosynthesis. Neovascularization, Pathologic / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 [14555767.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 11;22(5):749-55 [8139914.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6065-8 [7954447.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):837-43 [7547505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13543-8 [14578451.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):27-32 [15000492.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1198-203 [15026801.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7317-27 [9372963.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2371-81 [9528806.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4577-88 [9671467.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):58-65 [9695810.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):968-76 [10022839.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9637-41 [10449746.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):815-22 [10487839.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):933-8 [16189525.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):186-9 [16595146.001]
  • [Cites] Cancer Lett. 2006 Dec 8;244(2):203-10 [16469432.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):670-7 [10537105.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1332-40 [10728695.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Nature. 2000 Oct 5;407(6804):592-8 [11034201.001]
  • [Cites] J Cell Sci. 2000 Nov;113 ( Pt 22):3897-905 [11058077.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5929-33 [11085505.001]
  • [Cites] Nature. 2001 Feb 22;409(6823):1067-70 [11234019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7812-6 [11427735.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5703-6 [11479201.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6008-11 [11507043.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2569-77 [11745191.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1812-22 [11896613.001]
  • [Cites] J Urol. 2002 Jun;167(6):2598-602 [11992094.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):721-5 [12016143.001]
  • [Cites] Mol Carcinog. 2002 Sep;35(1):42-9 [12203366.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):473-83 [12498716.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):779-85 [12576450.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):677-82 [12640673.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4498-508 [12881706.001]
  • [Cites] J Pathol. 2003 Aug;200(5):561-7 [12898591.001]
  • [ErratumIn] Br J Cancer. 2009 Jul 21;101(2):377-8
  • (PMID = 19002177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Modulating Agents; 0 / Biomarkers, Tumor; 0 / Inhibitor of Differentiation Protein 1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2584935
  •  go-up   go-down


60. Nagle D: Anal squamous cell carcinoma in the HIV-positive patient. Clin Colon Rectal Surg; 2009 May;22(2):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal squamous cell carcinoma in the HIV-positive patient.
  • Epidermoid carcinoma of the anal canal is uncommon.
  • Modern therapy of HIV with highly active antiretroviral therapy (HAART) has improved the overall survival of HIV patients and allowed effective therapy for those who develop epidermoid carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 2005 Jul-Aug;49(4):405-15 [16124170.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):206-11 [16904522.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2780-9 [17638059.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):474-9 [18202423.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Nov;6(11):925-34 [18410393.001]
  • [Cites] AIDS Read. 2008 Apr;18(4):185-7 [18472440.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Mol Pathol. 1997 Feb;50(1):1-3 [9208805.001]
  • [Cites] South Med J. 2008 Nov;101(11):1185-6 [19088542.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] AIDS. 2000;14 Suppl 3:S189-95 [11086862.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] AIDS Read. 1999 May-Jun;9(3):204-8, 220 [12728907.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1305-9 [15484343.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1024-30; discussion 1031 [15585390.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] Open AIDS J. 2007;1:11-20 [18776956.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):186-92 [8463044.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • (PMID = 20436834.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780243
  • [Keywords] NOTNLM ; Epidermoid carcinoma of the anus / HIV / anal cancer
  •  go-up   go-down


61. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


62. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology


63. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT: Proteasome regulation of ULBP1 transcription. J Immunol; 2009 May 15;182(10):6600-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined NKG2D ligand expression in head and neck squamous cell carcinoma (HNSCC) cells and other cell lines.
  • We then studied how cancer treatments affected NKG2D ligand expression.
  • NKG2D ligand expression was not changed by most cancer-relevant treatments.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2004 Feb 15;172(4):2001-5 [14764662.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2175-82 [15026360.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1078-84 [15240696.001]
  • [Cites] J Gen Virol. 2004 Aug;85(Pt 8):2357-64 [15269377.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900 [15279774.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1495-9 [15381927.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7596-603 [15492287.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5583-90 [15494508.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1998 Mar 13;279(5357):1737-40 [9497295.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5091-8 [9710593.001]
  • [Cites] Immunity. 2001 Feb;14(2):123-33 [11239445.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 3;1526(1):10-2 [11287116.001]
  • [Cites] Eur J Immunol. 2001 Apr;31(4):1076-86 [11298332.001]
  • [Cites] Med Res Rev. 2001 Jul;21(4):245-73 [11410931.001]
  • [Cites] Nature. 2001 Sep 13;413(6852):165-71 [11557981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11521-6 [11562472.001]
  • [Cites] J Invest Dermatol. 2002 Apr;118(4):600-5 [11918705.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4023-8 [12124336.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4375-82 [9766667.001]
  • [Cites] Genes Dev. 1999 Jan 15;13(2):152-7 [9925639.001]
  • [Cites] Science. 1999 Apr 16;284(5413):499-502 [10205060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6879-84 [10359807.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):629-33 [15530773.001]
  • [Cites] J Exp Med. 2004 Nov 15;200(10):1325-35 [15545356.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):769-77 [15599854.001]
  • [Cites] Blood. 2005 May 1;105(9):3615-22 [15657183.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7278-84 [15905574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11805-10 [16091471.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):928-37 [16116470.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4611-7 [16177106.001]
  • [Cites] Oral Oncol. 2005 Nov;41(10):1013-20 [16139561.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5966-74 [16237090.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):802-11 [16108032.001]
  • [Cites] Hum Immunol. 2006 Mar;67(3):159-69 [16698438.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):962-72 [16601753.001]
  • [Cites] Semin Immunol. 2006 Jun;18(3):167-75 [16723257.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L222-31 [16473864.001]
  • [Cites] Int Immunol. 2006 Aug;18(8):1221-32 [16818466.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):848-55 [16750857.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9362-8 [17018588.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30419-30 [16901903.001]
  • [Cites] J Oral Pathol Med. 2007 Jan;36(1):43-7 [17181741.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62 [17183360.001]
  • [Cites] J Virol. 2007 Jan;81(2):474-82 [17079298.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):961-9 [17202358.001]
  • [Cites] PLoS One. 2007;2(6):e518 [17565371.001]
  • [Cites] Blood. 2007 Jul 15;110(2):606-15 [17405908.001]
  • [Cites] Immunology. 2007 Aug;121(4):439-47 [17614877.001]
  • [Cites] Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8 [17635809.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):737-44 [17673918.001]
  • [Cites] Cancer Immun. 2007;7:17 [17948965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1686-91 [18223157.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1546-54 [18316620.001]
  • [Cites] Immunity. 2008 Apr;28(4):571-80 [18394936.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3520-8 [18519785.001]
  • [Cites] J Exp Med. 2009 Feb 16;206(2):287-98 [19171762.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6178-86 [12414645.001]
  • [Cites] J Exp Med. 2002 Dec 2;196(11):1399-402 [12461075.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Structure. 2003 Apr;11(4):411-22 [12679019.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 23;305(1):129-35 [12732206.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1245-53 [12756263.001]
  • [Cites] Eur J Immunol. 2003 Jul;33(7):2033-43 [12884870.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1389-96 [12714493.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5813-27 [12947388.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] Int J Radiat Biol. 2003 Aug;79(8):655-61 [14555348.001]
  • [Cites] Immunity. 2003 Oct;19(4):469-77 [14563312.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8996-9006 [14695218.001]
  • [CommentIn] J Immunol. 2009 Oct 1;183(7):4145; author reply 4145-6 [19767562.001]
  • (PMID = 19414815.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE011139; United States / NIDCR NIH HHS / DE / DE11139; United States / NIAID NIH HHS / AI / R01 AI050656-05; United States / NIAID NIH HHS / AI / AI050656; United States / NIAID NIH HHS / AI / R01 AI050656; United States / NCI NIH HHS / CA / T32 CA009509; United States / NIDCR NIH HHS / DE / DE011139-10; United States / NIDCR NIH HHS / DE / R01 DE011139-10; United States / NCI NIH HHS / CA / T32-CA09509; United States / NIAID NIH HHS / AI / AI050656-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / GPI-Linked Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / KLRK1 protein, human; 0 / Membrane Proteins; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / ULBP1 protein, human; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ NIHMS126306; NLM/ PMC2748925
  •  go-up   go-down


64. Shetty G, Kendall C, Shepherd N, Stone N, Barr H: Raman spectroscopy: elucidation of biochemical changes in carcinogenesis of oesophagus. Br J Cancer; 2006 May 22;94(10):1460-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean spectra obtained from selected regions demonstrate increased levels of glycogen in the squamous area compared with increased DNA levels in the abnormal region.
  • [MeSH-minor] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Biopsy. Carcinoma, Squamous Cell / metabolism. DNA, Neoplasm / metabolism. Female. Glycogen / metabolism. Humans. Lipid Metabolism. Male. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Anal Chem. 2002 Jul 1;74(13):3160-7 [12141678.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5375-80 [12235010.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):106-8 [12838309.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1729-35 [14583777.001]
  • [Cites] Appl Spectrosc. 2003 Jan;57(1):20A-42A [14610929.001]
  • [Cites] J Am Chem Soc. 2004 Mar 3;126(8):2399-408 [14982446.001]
  • [Cites] Faraday Discuss. 2004;126:141-57; discussion 169-83 [14992404.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):91-5 [8836727.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1033-6 [9672325.001]
  • [Cites] Gut. 1998 Aug;43(2):216-22 [10189847.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1187-97 [15568939.001]
  • [Cites] ANZ J Surg. 2005 Jul;75(7):513-9 [15972033.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • (PMID = 16622450.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 9005-79-2 / Glycogen
  • [Other-IDs] NLM/ PMC2361283
  •  go-up   go-down


65. Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol; 2010;5:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
  • PURPOSE: To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course chemoradiation (CRT).
  • METHODS: From 1991 to 2005, 58 patients with anal cancer were curatively treated with CRT.
  • Significant anal pain or fecal incontinence was infrequently reported.
  • CONCLUSIONS: Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and long-term global QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Quality of Life. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):282-5 [3986477.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):107-13 [17707936.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):239-43 [10580870.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(2):189-93 [17189954.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1564-73 [17521904.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 20492729.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2883545
  •  go-up   go-down


66. Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J, Silver A: Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer; 2007 Dec 15;121(12):2668-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
  • Human papilloma virus (HPV) infection is considered as an important aetiological factor for anal squamous cell carcinoma (ASCC) but is not sufficient for tumour progression.
  • This carcinoma is poorly understood at the molecular level.
  • [MeSH-major] Anus Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Papillomaviridae / isolation & purification. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17721920.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


67. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ortholan C, Ramaioli A, Peiffert D, Lusinchi A, Romestaing P, Chauveinc L, Touboul E, Peignaux K, Bruna A, de La Roche G, Lagrange JL, Alzieu C, Gerard JP: Anal canal carcinoma: early-stage tumors &lt; or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy.
  • PURPOSE: To investigate the clinical history, management, and pattern of recurrence of very early-stage anal canal cancer in a French retrospective survey.
  • METHODS: The study group consisted of 69 patients with Stage Tis and T1 anal canal carcinoma < or =1 cm treated between 1990 and 2000 (12 were in situ, 57 invasive, 66 Stage N0, and 3 Stage N1).
  • These small anal cancers could be treated by RT using a small volume and moderate dose (40-50 Gy for subclinical lesions and 50-60 Gy for T1).
  • [MeSH-major] Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage